Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-744 alone or with ruxolitinib/navitoclax in myelofibrosis
NCT04454658Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2020
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 1, open-label trial of ABBV-744 in myelofibrosis (MF) (5 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Adverse Events at 1 year. Started Nov 2020; status: active, not recruiting.
02
Drugs
ABBV-744
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04454658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454658.